Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (August 2024)
29 slides from Matinas Biopharma's investor presentation, Aug 14, 2024
Slide 1: Matinas BioPharma Corporate Presentation August 2024
MATINAS BIOPHARMA Corporate Presentation August 2024 www.matinasbiopharma.com NYSE American: MTNB
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other sta
Slide 3: Investment Thesis: LNC Delivery Unlocks Therapeutic Value
Investment Thesis: LNC Delivery Unlocks Therapeutic Value a > Intracellular delivery Lipid Nanocrystals > Oral administration > Less toxicity (LNCs) > Targeting beyond the liver MAT2203 Clinical Validation Pipeline Products of LNC Capabilities and Opportunities > > A * Oral Amphotericin B - without
Slide 4: Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform
Lipid Nanocrystals (LNCs): A Clinically Validated Intracellular Delivery Platform i PEE sey ie Beppe if _ ue ne Meus eZ ronson | OE nities Viniee 4 cone | ne We 7 lig Hydrophobic drug L, y ie wy De Byer Stable, phospholipid- calcium crystalline nanocrystals Phosphatidylserine 150 - 350 nm COPYRIGHT
Slide 5: Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery
Phosphatidylserine Enables Cellular Targeting and Intracellular Delivery Stressed Cells Externalize PS Normally, PS. is confined to the inner layer (facing cytosol) CELL MEMBRANE CYTOSOL With cellular stress or injury, PS moves from the inner layer to the outer layer of the cell membrane i ion = Inf
Slide 6: MAT2203 Oral Amphotericin B
MAT2203 Oral Amphotericin B Clinical Validation of LNC Delivery COPYRIGHT MATINAS BIOPHARMA - 2024 BIOPHARMA
Slide 7: The Growing Threat of Invasive Fungal Infections (IFIs)
The Growing Threat of Invasive Fungal Infections (IFls) Wall Street Journal Dangerous Fungi Are Spreading Across U.S. as Temperatures Rise Nature Reviews Microbiology 2022 ssi ‘The Battle Against the Fungal Apocalypse Is Tackling the emerging threat of Just Beginning ia resistance to human health ‘S
Slide 8: MAT2203: Unlocking the Full Potential of Amphotericin B
MAT2203: Unlocking the Full Potential of Amphotericin B Innate Amphotericin B IV Amphotericin B — Unlocked Characteristics Limitations = Potential POTENT - Only available through Giellet epetelnelly Y Y Y 2) broad-spectrum fungicidal Minimal drug-drug interactions Low propensity for resistance Activ
Slide 9: EnACT: Phase 2 Clinical Validation of Safety and Efficacy
EnACT: Phase 2 Clinical Validation of Safety and Efficacy EnACT Clinical Data in Cryptococcal Meningitis Validates the Use of the LNC Platform to Enable Oral Administration and Overcome Toxicity ENS BBN Exceeded the primary All patients completing No breakthrough Survival at Day 30 MAT2203 was safe
Slide 10: Results of EnACT Published in Highly Regarded Peer-Reviewed Journal
Results of EnACT Published in Highly Regarded Peer-Reviewed Journal Clinical Infectious Diseases Fk! 2 h : | | ) hivma) a MAJOR ARTICLE wal DSA America hw medicine assoostion OXFORD Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial David R. Boulware,"° Mu
Slide 11: MAT2203 Expanded Access Program - Targeted Treatment of IFIs Throughout the Body
Mucor nidicola Pansinusitis (head) Aspergillus calidoustus Pulmonary aspergillosis Fusarium Pneumonia Rhizopus microsporus, Aspergillus fumigatus Deep tissue infection Mucor and Aspergillus species Pneumonia Rhizopus oryzea (2 Cases) Pulmonary mucormycosis Candida glabrata Retroperitoneal abscess Ca
Slide 12: MAT2203 Expanded Access/Compassionate Use Program
MAT2203 Expanded Access/Compassionate Use Program Demonstrated Efficacy in Treatment of Patients with Limited Treatment Options 31 patients with no other treatment options have enrolled to receive or have completed treatment with MAT2203 with 6 additional requests under evaluation — Notable Healthca
Slide 13: Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203
Compassionate Use - Recovery from IV Amphotericin B Kidney Toxicity with MAT2203 A 38 y/o female with systemic lupus eryth on chronic hydroxychloroquine and predni: p { with a progressively enlarging wound on her left foot. 07/2022: Patient admitted twice for dysgeusia, 05/2022: nausea, vomiting, hy
Slide 14: High Unmet Medical Need in Invasive Aspergillosis with Limited Treatment Options
High Unmet Medical Need in Invasive Aspergillosis (IA) with Limited Treatment Options ¢ lAisa serious, life-threatening fungal infection that occurs primarily in severely immunocompromised patients with hematologic malignancies and transplant recipients = ~15,000 new cases per year in the U.S. = WHO
Slide 15: MAT2203 Regulatory and Development Strategy
MAT2203 Regulatory and Development Strategy Near-term development strategy refined to narrow initial target indication: treatment of invasive aspergillosis in patients with limited treatment options (azole-intolerant, azole-resistant, or not effectively managed with an azole) — Potential registratio
Slide 16: FDA-Agreed Phase 3 Study Design in Invasive Aspergillosis (the ORALTO Trial)
FDA-Agreed Phase 3 Study Design in Invasive Aspergillosis (IA) (the “ORALTO” Trial) > To demonstrate that initial treatment with IV LAMB followed by step-down to oral MAT2203 is comparable to (noninferior) SoC treatment in adult patients with Invasive Aspergillosis (IA) who are unable to receive tre
Slide 17: MAT2203 Value Proposition
MAT2203 Value Proposition with a potent fungicidal agent LCM ¢ Treatment of Other IFis * Prophylaxis = VALUE Vv Near-Term Development Strategy: Focused strategy on Phase 3 registration trial in Invasive Aspergillosis in patients with limited or no treatment options under the Limited Population Pathw
Slide 18: LNCs Beyond Infection
LNCs Beyond Infection Efficient and Safe Delivery of Small Oligonucleotides and Chemotherapeutics in Inflammation and Oncology MATINAS BIOPHARMA COPYRIGHT MATINAS BIOPHARMA - 2024
Slide 19: Unlocking the Full Potential of the LNC Platform
Unlocking the Full Potential of the LNC Platform Proven Delivery of Cargo Potential Therapeutic Applications | INFECTION i * MAT2203 * Anti-infectives Oral Formulations "ea Anat of Anti-Infectives » Autoimmune diseases * Neuro-inflammatory diseases ° Acute/chronic Inflammatory diseases Oral Delivery
Slide 20: LNCs are Avidly Taken up by Innate Immune Cells - Potential in Inflammation
LNCs are Avidly Taken up by Innate Immune Cells - Potential in Inflammation Ex-vivo LNC Uptake in Human Whole Blood 100 99.9 97.5 70.8 63.1 | 38 >, = | = Monocytes S fo 9 3 to} toy Percent of cells with uptake N oO Neutrophils 80 ug/mL LNC 512 ng/mL Cy5-labeled siRNA cargo 94:5 81.6 39.9 0.2 0.0 0.3
Slide 21: Effect of Oral LNC IL-17A RNAi in a Murine Psoriasis Model
Effect of Oral LNC IL-17A RNAi in a Murine Imiquimod (IMQ) Psoriasis Model + 4 Day 7 *-p< 0,004 (Day 4-7) e C9 Back skin scale score 9 Back skin scale score ny 0 8 Naive IMQ WNC4 — LNC2- La Ab Redness 4 4 *~p < 0.004 (Day 4-7) Day 7 23 % ° 3 3 3 B2 §2 3 3 Ss 4 3 1 1 0 8 Naive MQ UNC. LNC2 LAA Days o
Slide 22: Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model
Disease Activity Index Effect of Oral LNC-TNFa RNAi in a Murine DSS Acute Colitis Model ag, Female C57BL/6 mice (n=55) 5-4 4- ot etee 3-4 244 1-4 o- 6 Groups Untreated control DSS alone DSS + oral LNC 1 DSS + oral LNC 2 DSS + oral Scrambled LNCs DSS + anti-TNFa Ab 0.167 mg/mouse on day 0, 4 and 6 pr
Slide 23: LNCs Target PS on Tumor Cells - Potential Opportunities in Oncology
LNCs Target PS on Tumor Cells - Potential Opportunities in Oncology Healthy Cell Tumor Cell © Phosphatidylserine (PS) PS is confined to the interior leaflet of the cellular plasma membrane PS is exposed on the surface of tumor cells LNCs nottaken up by normal cells LNCs avidly taken up by cells expr
Slide 24: In vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Melanoma Model
/n vivo Therapeutic Efficacy of Oral Docetaxel LNCs in a Murine Syngeneic Melanoma Model 000+ Female C57BL/6 mice implant (n= 40) cells : ee Ag, DayO Day 5 Day10 Day 14 ~ /-Docetaxel J 1500 “High Dose LNC-docetaxel £ -@ Low Dose LNC-docetaxel Ciena) 4 Docetaxel 0.15 mg/mouse von day 5 and day 10 |_|
Slide 25: Oral LNC-Docetaxel Markedly Reduces Toxicity
Oral LNC-Docetaxel Markedly Reduces Toxicity % Change in Body Weight 25% 1V Docetaxel ‘Study End - a Day 22 4g, Healthy C57BL/6 mice (n= 24) Body weight it wrheaiee Oral saline (control) not different than control Docetaxel 0.6 mg/mouse iv q weekx3 -@>- Control =A LNC Docetaxel —@— |V Docetaxel » “(
Slide 26: Recent Key Advances Highlight Broader Applicability of LNC Platform Capabilities
Recent Key Advances Highlight Broader Applicability of LNC Platform Capabilities > Successful in vivo oral delivery of LNC-docetaxel in a ncology melanoma tumor model * Reductions in tumor weight and volume comparable to IV docetaxel * No adverse effects on body weight or hematologic parameters > Co
Slide 27: Expanding LNC Intellectual Property Portfolio
Expanding LNC Intellectual Property Portfolio Increasing Patent Portfolio to Increase Protection and Exclusivity vie ces (© MAT2203 potentially entitled Owned and Licensed Recent patent to 12+ years of marketing Global Platform IP with applications based on exclusivity potential protection formulati
Slide 28: Experienced Leadership Team
Experienced Leadership Team EXECUTIVE TEAM Jerome D. Jabbour, J.D. Chief Executive Officer Gre " James Ferguson, M.D. Chief Medical Officer AMGEN Hy Astrazeneca? Thomas Hoover, MBA Chief Business Officer Chief Development Officer U NovarTIs SEMILLENPO *Ssunovion nps The : Medicines ‘Company Hui Liu,
Slide 29: Investment Thesis
Investment Thesis Financial Summary Runway into Q2 2025 $14.3M in Cash, Cash Equivalents and Marketable Securities at 6/30/24 ©) Non-Dilutive Financing Options e 2024 Milestones | Q2 - Additional /7 vivo Oral Delivery of Small Oli: Q2 - /nvivoEvaluation of Additional Chemo-toxic Agents Delivered wit
Matinas BioPharma Holdings — Investor Presentation (August 2024) on 6ix